Bak-Leong Goh

Prof. Dr. Bak-Leong Goh


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
Verified
Journal Article
Open access
JCJohn H. Crabtree
John H. Crabtree
BSBadri M. Shrestha
Badri M. Shrestha
KCKai-Ming Chow
Kai-Ming Chow
AFAna E. Figueiredo
Ana E. Figueiredo
JPJohan V. Povlsen
Johan V. Povlsen
FDFrank J.M.F. Dor
Frank J.M.F. Dor

1 July 2010 in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
Verified
Journal Article
Open access
PDF file
AFAna Figueiredo
Ana Figueiredo
BGBak-Leong Goh
Bak-Leong Goh
SJSarah Jenkins
Sarah Jenkins
DJDavid Johnson
David Johnson
RMRobert Mactier
Robert Mactier
MWMartin Wilkie
Martin Wilkie

13 October 2005 in Nephrology
Verified
Journal Article
Closed access
PDF file
LOLoke Meng Ong
Loke Meng Ong
LHLai Seong Hooi
Lai Seong Hooi
TLTeck Onn Lim
Teck Onn Lim
BGBak-Leong Goh
Bak-Leong Goh
GAGhazali Ahmad
Ghazali Ahmad
ZMZaki Morad
Zaki Morad

1 March 2020 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
KMKarine E. Manera
Karine E. Manera
DJDavid W. Johnson
David W. Johnson
JCJonathan C. Craig
Jonathan C. Craig
JSJenny I. Shen
Jenny I. Shen
TGTalia Gutman
Talia Gutman
ZBZeeshan Butt
Zeeshan Butt

1 March 2020 in Kidney International Supplements
Verified
Journal Article
Closed access
RPRoberto Pecoits-Filho
Roberto Pecoits-Filho
IOIkechi G. Okpechi
Ikechi G. Okpechi
JDJo-Ann Donner
Jo-Ann Donner
DHDavid C.H. Harris
David C.H. Harris
HAHarith M. Aljubori
Harith M. Aljubori
DJDavid W. Johnson
David W. Johnson

1 April 2019 in Kidney International
Verified
Journal Article
Open access
DHDavid C.H. Harris
David C.H. Harris
SDSimon J. Davies
Simon J. Davies
FFFredric O. Finkelstein
Fredric O. Finkelstein
VJVivekanand Jha
Vivekanand Jha
JDJo-Ann Donner
Jo-Ann Donner
MZMing-Hui Zhao
Ming-Hui Zhao
The global nephrology community recognizes the need for a cohesive strategy to address the growing problem of end-stage kidney disease (ESKD). In March 2018, the International Society of Nephrology hosted a summit on integrated ESKD care, including 92 individuals from around the globe with diverse expertise and professional backgrounds. The attendees were from 41 countries, including 16 participants from 11 low- and lower-middle-income countries. The purpose was to develop a strategic plan to improve worldwide access to integrated ESKD care, by identifying and prioritizing key activities across 8 themes: (i) estimates of ESKD burden and treatment coverage, (ii) advocacy, (iii) education and training/workforce, (iv) financing/funding models, (v) ethics, (vi) dialysis, (vii) transplantation, and (viii) conservative care. Action plans with prioritized lists of goals, activities, and key deliverables, and an overarching performance framework were developed for each theme. Examples of these key deliverables include improved data availability, integration of core registry measures and analysis to inform development of health care policy; a framework for advocacy; improved and continued stakeholder engagement; improved workforce training; equitable, efficient, and cost-effective funding models; greater understanding and greater application of ethical principles in practice and policy; definition and application of standards for safe and sustainable dialysis treatment and a set of measurable quality parameters; and integration of dialysis, transplantation, and comprehensive conservative care as ESKD treatment options within the context of overall health priorities. Intended users of the action plans include clinicians, patients and their families, scientists, industry partners, government decision makers, and advocacy organizations. Implementation of this integrated and comprehensive plan is intended to improve quality and access to care and thereby reduce serious health-related suffering of adults and children affected by ESKD worldwide.